Experimental drug combo aims to make radiation safer for kids with deadly brain tumor
NCT ID NCT02864888
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding two experimental drugs (Atengenal and Astugenal) to standard radiation affects heart rhythm in children aged 3–21 with newly diagnosed diffuse intrinsic brainstem glioma. The study will enroll 30 participants and monitor heart electrical activity via ECGs. It runs alongside a larger efficacy study comparing the combination to radiation alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atengenal (A10) and Astugenal (AS2-1) combined with radiation
- What this could lead to
- If successful, this could point toward a safer way to treat brainstem glioma in children by combining antineoplaston therapy with radiation.
- What could go wrong
- This is a small, early-stage safety study (30 participants) focused on heart rhythm effects, not yet testing whether the treatment actually works. The antineoplaston approach is controversial and unproven for this cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN STEM GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.